GO
Loading...

What's in Eli Lilly's Pharma Pipeline?

Wednesday, 25 Jul 2012 | 7:22 AM ET

John Lechleiter, Eli Lilly chairman, president & CEO, breaks down his company's Q2 earnings, meeting revenue expectations of $5.6 billion. He also discusses several new drugs in phase three development.